How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

Joshua J Neumiller; Rita R Kalyani

doi:10.2215/CJN.05340419

How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1667-1669. doi: 10.2215/CJN.05340419. Epub 2019 Oct 1.

Authors

Joshua J Neumiller¹, Rita R Kalyani²

Affiliations

¹ Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; and.
² Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland.

No abstract available

Keywords: Canagliflozin; Hypoglycemic Agents; Sodium-Glucose Transporter 2; cardiovascular disease; cardiovascular outcomes; chronic kidney disease; chronic renal insufficiency; diabetes; end stage kidney disease; type 2 diabetes.

MeSH terms

Canagliflozin / therapeutic use*
Diabetic Nephropathies / drug therapy*
Humans
Randomized Controlled Trials as Topic
Renal Insufficiency, Chronic / drug therapy*
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin